Pharmacodynamic Effects, Safety and Tolerability of Cilobradine, to Healthy Male and Female Volunteers, With an Intra-individual Comparison to Moxifloxacin in a Subset of Volunteers

Phase 1

Completed

• Conditions: Healthy
• Interventions: Drug: Cilobradine, high, film-coated tablets; Drug: Moxifloxacin, film-coated tablets; Drug: Cilobradine, low, film-coated tablets; Drug: Placebo, film-coated tablets

• Registration Number: NCT02264015
• Lead Sponsor: Boehringer Ingelheim

Brief Summary

Incidence of visual phenomena, heart rate at rest, safety (with particular emphasis on QT analysis of ECGs), and pharmacokinetic parameters

Detailed Description

Not available

Study Timeline

• Study Start: 2004-01
• Primary Completion: 2004-05
• Status Verified: 2014-10
• Study First Submitted: 2014-10-13
• Study First Submitted QC: 2014-10-13
• Last Update Submitted: 2014-10-13
• Study First Posted: 2014-10-15
• Last Update Posted: 2014-10-15

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 125

Inclusion Criteria

1. Healthy males and females according to the following criteria:

   Based upon a complete medical history, including the physical examination, vital signs (blood pressure (BP), pulse rate (PR)), 12-lead Electrocardiogram (ECG), clinical laboratory tests

   1.1 No finding deviating from normal and of clinical relevance

   1.2 No evidence of a clinically relevant concomitant disease

2. Age ≥21 and Age ≤55 years

3. BMI ≥18.5 and BMI < 30 kg/m2 (Body Mass Index)

4. Resting Heart rate (HR) (after 10 min. in the supine position) of equal or more than 60 bpm

5. Females: post-menopausal or those who have had a hysterectomy (plus a negative pregnancy test)

6. Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice (GCP) and the local legislation

Read More

Exclusion Criteria

1. Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological, ophthalmological, or hormonal disorders

2. Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders

3. History of relevant orthostatic hypotension, fainting spells or blackouts

4. Chronic or relevant acute infections

5. History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator

6. Intake of drugs with a long half-life (>24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration or during the trial

7. Use of drugs which might reasonably influence the results of the trial based on the knowledge at the time of protocol preparation within 10 days prior to administration or during the trial

8. Participation in another trial with an investigational drug within two months prior to administration or during the trial

9. Smoker (more than 10 cigarettes or 3 cigars or 3 pipes/day)

10. Inability to refrain from smoking on trial days

11. Alcohol abuse

12. Drug abuse

13. Blood donation (more than 100 mL within four weeks prior to administration or during the trial)

14. Excessive physical activities (within one week prior to administration or during the trial)

15. Any laboratory value outside the reference range that is of clinical relevance.

    Exclusion criteria specific for this study:

16. Subjects at increased risk for development of cardiac arrhythmia (e.g. family history of long QT syndrome or sudden cardiac death)

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Cilobradine high	Cilobradine, high, film-coated tablets	-
Moxifloxacin	Moxifloxacin, film-coated tablets	-
Cilobradine low	Cilobradine, low, film-coated tablets	-
Placebo	Placebo, film-coated tablets	-

Primary Outcome Measures

Name	Time	Method
Change in heart rate at rest	Pre dose, up to 12 hours after drug administration
Incidence of visual phenomena	Up to 12 days after last scheduled study day	Reported as adverse events

Secondary Outcome Measures

Name	Time	Method
Investigator assessed tolerability on a 4 point scale	Up to 12 days after last scheduled study day
Characteristics of visual phenomena on a special questionnaire	Up to 12 days after last scheduled study day
Number of participants with abnormal changes in clinical laboratory parameters	Up to 12 days after last scheduled study day
Maximum plasma concentration following the first dose (Cmax)	Up to 24 hours after drug administration
Area under the concentration-time curve of the analyte in plasma from zero time to 24 hours (AUC0-24)	Up to 24 hours after drug administration
Mean residence time of the analyte in the body after oral administration (MRTpo)	Up to 24 hours after drug administration
Number of participants with abnormal findings in physical examination	Up to 12 days after last scheduled study day
Number of participants with adverse events	Up to 12 days after last scheduled study day
Number of participants with abnormal findings in electrocardiogram (ECG)	Up to 12 days after last scheduled study day
Terminal half-life (t1/2)	Up to 24 hours after drug administration
Apparent volume of distribution during the terminal phase λz following extravascular administration (Vz/F)	Up to 24 hours after drug administration
Number of participants with clinically significant changes in vital signs	Up to 12 days after last scheduled study day
Time from first dose to the maximum plasma concentration (tmax)	Up to 24 hours after drug administration
Apparent clearance of the analyte in plasma following extravascular administration (CL/F)	Up to 24 hours after drug administration